Literature DB >> 16232005

A cost-benefit simulation model of coverage for bariatric surgery among full-time employees.

Eric A Finkelstein1, Derek S Brown.   

Abstract

OBJECTIVE: To use a simulation model to estimate the costs and benefits of bariatric surgery among full-time employees. STUDY
DESIGN: Multivariate regression analysis of nationally representative survey data sets to estimate the costs of obesity and a simulation model of the number of years until breakeven under alternate assumptions about the costs and benefits of bariatric surgery.
METHODS: We used a 2-part model to estimate medical costs of obesity based on the 2000-2001 Medical Expenditure Panel Survey. We estimated work loss with a negative binomial regression based on the 2002 National Health Interview Survey. Using these results, we simulated the expected number of years required for a bariatric surgery procedure to become cost saving.
RESULTS: Nine percent of the full-time US workforce, or 29% of the obese workforce, is eligible for bariatric surgery. Obese workers eligible for bariatric surgery have 5.1 (P < .01) additional days of work loss and USD 2230 (in 2004 dollars) (P < .01) higher annual medical costs than persons of normal weight.
CONCLUSION: Although the cost implications of bariatric surgery among full-time employees depend on many factors, the simulations reveal that 5 or more years of follow-up are most likely required for these operations to become cost saving unless the employee bears a significant fraction of the total costs of the surgery.

Entities:  

Mesh:

Year:  2005        PMID: 16232005

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  14 in total

Review 1.  Bariatric surgery: cost-effectiveness and budget impact.

Authors:  Lorenzo Terranova; Luca Busetto; Annarita Vestri; Marco Antonio Zappa
Journal:  Obes Surg       Date:  2012-04       Impact factor: 4.129

2.  A cost-benefit analysis of bariatric surgery on the South Plains region of Texas.

Authors:  Bradley T Ewing; Mark A Thompson; Mitchell S Wachtel; Eldo E Frezza
Journal:  Obes Surg       Date:  2011-05       Impact factor: 4.129

3.  Utilization rate of bariatric surgery in an employee-based healthcare system following surgery coverage.

Authors:  Keith Kim; Vickie White; Cynthia K Buffington
Journal:  Obes Surg       Date:  2010-11       Impact factor: 4.129

Review 4.  Simulation models of obesity: a review of the literature and implications for research and policy.

Authors:  D T Levy; P L Mabry; Y C Wang; S Gortmaker; T T-K Huang; T Marsh; M Moodie; B Swinburn
Journal:  Obes Rev       Date:  2010-10-26       Impact factor: 9.213

5.  The economic impact of morbid obesity.

Authors:  Eldo E Frezza; Mitchell S Wachtel
Journal:  Surg Endosc       Date:  2009-01-30       Impact factor: 4.584

Review 6.  Surgical approaches to the treatment of obesity.

Authors:  John B Dixon; Nora E Straznicky; Elisabeth A Lambert; Markus P Schlaich; Gavin W Lambert
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-07-05       Impact factor: 46.802

7.  Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity.

Authors:  Tom C Hall; Mike G C Pellen; Peter C Sedman; Prashant K Jain
Journal:  Obes Surg       Date:  2010-09       Impact factor: 4.129

Review 8.  Direct medical cost of overweight and obesity in the USA: a quantitative systematic review.

Authors:  A G Tsai; D F Williamson; H A Glick
Journal:  Obes Rev       Date:  2011-01       Impact factor: 9.213

9.  Cost-effectiveness of bariatric surgical procedures for the treatment of severe obesity.

Authors:  Bruce C M Wang; Edwin S Wong; Rafael Alfonso-Cristancho; Hao He; David R Flum; David E Arterburn; Louis P Garrison; Sean D Sullivan
Journal:  Eur J Health Econ       Date:  2013-03-24

10.  Cost-effectiveness of bariatric surgery for severely obese adults with diabetes.

Authors:  Thomas J Hoerger; Ping Zhang; Joel E Segel; Henry S Kahn; Lawrence E Barker; Steven Couper
Journal:  Diabetes Care       Date:  2010-09       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.